Biliary Tract Cancer Market to Register Stunning Growth by 2032, Examines DelveInsight | Key Companies to Watch Out - Merck, AstraZeneca, Taiho Oncology, Basilea, Eisai, Zymeworks, BeiGene, Xencor, BMS, Leap
28 août 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Biliary Tract Cancer Market to Register Stunning Growth by 2032, Examines DelveInsight | Key Companies to Watch Out - Merck, AstraZeneca, Taiho...
Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes
22 juin 2023 16h05 HE
|
Compass Therapeutics
BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
04 mai 2023 08h30 HE
|
Compass Therapeutics
Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC). Top line data is expected in the first half...
Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
19 avr. 2023 08h30 HE
|
Compass Therapeutics
BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023
19 janv. 2023 17h00 HE
|
Compass Therapeutics
Compass to Host Investor Event on Monday, January 23rd at 8:30am ET CTX-009 in combination with paclitaxel demonstrated a 37.5% overall response rate (ORR) in 24 patients with BTC treated in the...
Compass Therapeutics to Present at the 13th Annual Wedbush PacGrow Healthcare Conference
02 août 2022 08h00 HE
|
Compass Therapeutics
BOSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Compass Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
01 août 2022 08h00 HE
|
Compass Therapeutics
Phase 2/3 trial of CTX-009 (DLL4 X VEGF-A bispecific) and paclitaxel in biliary tract cancer (BTC) anticipated to begin in the United States in Q3 2022A Phase 2 trial of CTX-009 as a monotherapy in...
Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
01 juin 2022 08h00 HE
|
Cornerstone Pharmaceuticals, Inc.
Cranbury, NJ, June 01, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael...
European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer
24 mai 2022 11h04 HE
|
Cornerstone Pharmaceuticals, Inc.
Cranbury, NJ, May 24, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael...
Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference
23 mai 2022 08h00 HE
|
Compass Therapeutics
BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...